FDA Advisory Committee Recommends Including Subclade K Variant in Fall 2024 Flu Vaccines
核心洞察
A Food and Drug Administration (搜索) advisory committee voted Thursday to recommend including subclade K (搜索), a highly transmissible flu variant, in vaccines beginning this fall.
The CDC reported reduced vaccine effectiveness this season, with rates of 38-41% for children and 22-34% for adults against outpatient visits, attributed partly to the subclade K (搜索) variant.
Subclade K (搜索), a newly emerged subgroup within the H3N2 (搜索) family, has become the dominant flu variant in the Northern Hemisphere and caused earlier-than-usual surges globally.
A Food and Drug Administration (搜索) advisory committee voted Thursday to recommend including subclade K (搜索), a highly spreadable flu variant, in vaccines beginning this fall, following similar guidance from the World Health Organization. The decision comes as this variant is believed to be a key factor behind reduced vaccine effectiveness during the current flu season.
Reduced Vaccine Effectiveness Drives Policy Change
The Centers for Disease Control and Prevention (搜索) reported in its Morbidity and Mortality Weekly Report that influenza (搜索) vaccine effectiveness was significantly lower this season compared to recent years. For children and adolescents, vaccines showed 38% to 41% effectiveness for preventing outpatient visits and 41% for preventing hospitalization. Adult protection rates were even lower, ranging from 22% to 34% against influenza-associated outpatient visits and 30% against hospitalization.
Despite these reduced effectiveness rates, the CDC emphasized that "these findings demonstrate that influenza (搜索) vaccination still provides protection against influenza" and continues to recommend vaccination. During last year's flu season, vaccinations prevented an estimated 5 million medical visits, 180,000 hospitalizations and 12,000 deaths, according to CDC data.
The current flu season has proven particularly severe, with the CDC estimating at least 26 million illnesses, 340,000 hospitalizations and 21,000 deaths between October 1 and February 28.
Subclade K Emerges as Dominant Strain
Dr. Lisa Grohskopf, a medical officer in the CDC's Influenza (搜索) Division, confirmed at the committee meeting that subclade K (搜索) has become the dominant flu variant in the Northern Hemisphere this year. This newly emerged subgroup belongs to the H3N2 (搜索) family, a common flu strain that has affected humans for decades.
The variant has been responsible for earlier-than-usual flu surges across multiple regions, including the United States, Japan, the United Kingdom, and other parts of Europe. Health officials in the U.K., citing preliminary flu data, indicated that subclade K (搜索) may spread more easily than other versions of the illness, contributing to increased hospitalizations and higher test positivity rates.
Clinical Impact and Transmissibility Concerns
Dr. Scott Roberts, a Yale Medicine (搜索) infectious diseases specialist, described the current situation's severity: "By some metrics, this is the worst we have had in years and possibly, decades in terms of inpatient flu numbers and test positivity rates at the hospital."
However, Roberts clarified that the increased impact appears related to transmissibility rather than severity. "The reason people are saying 'super flu' is because it's a bad flu wave and many people are getting infected and hospital admissions are high," he explained. "That's all reflective of the fact that it's more mutated and there's increased transmissibility, not that it's more severe."
Roberts noted he hasn't observed data indicating that subclade K (搜索) causes more severe illness compared to other flu variants.
Challenges in Vaccine Development
The vaccine strain selection process faces inherent challenges due to viral mutation patterns. As noted by the University of Minnesota's Center for Infectious Disease Research and Policy, viruses mutate frequently, meaning there's no guarantee that variants selected during committee meetings will match those circulating during the subsequent flu season.
The six-month vaccine development timeline necessitates strain selection decisions in February or March, well before the following flu season begins. Arnold Monto, a University of Michigan epidemiologist and acting chair of the Vaccines and Related Biological Products Advisory Committee, acknowledged these complexities: "We've had a very efficient meeting in a very complicated year where we were reminded about how difficult strain selection is. It's a little bit of science, a little bit of luck."